NCT04083534View on ClinicalTrials.gov

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions

Relapsed Multiple MyelomaRefractory Multiple Myeloma

Interventions

DRUG

REGN5459

Administered by intravenous (IV) infusion

Trial Locations (7)

10029

Regeneron Study Site, New York

46202

Regeneron Study Site, Indianapolis

48109

Regeneron Study Site, Ann Arbor

53226

Regeneron Study Site, Milwaukee

55905

Regeneron Study Site, Rochester

75390

Regeneron Study Site, Dallas

77030

Regeneron Study Site, Houston

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04083534 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | Biotech Hunter | Biotech Hunter